![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 300, Issue 1, 195-199, January 2002
Department of Microbiology, School of Medicine, University of Nevada, Reno, Nevada
| |
Abstract |
|---|
|
|
|---|
Fungal infections are common in patients with acquired immunodeficiency syndrome and pose a major health management problem. There is a need for identification of new antifungals to complement the limited current repertoire and to combat newly arising resistant fungal strains. We have identified a novel antifungal activity for the antiarrhythmic drug amiodarone. Extensive characterization of this activity shows that amiodarone exhibits a growth inhibition for several diverse fungi, including species of Cryptococcus, Saccharomyces, Aspergillus, Candida, and Fusarium. The antifungal activity was shown to be fungicidal; Cryptococcus neoformans treated with amiodarone lost viability within hours of drug exposure. Growth inhibition could be suppressed by addition of very high concentrations (10 mM) of calcium to the medium, suggesting that disruption of calcium homeostasis was involved in the antifungal activity. Direct measurement of radiolabeled calcium efflux showed that addition of amiodarone resulted in an immediate efflux of cellular calcium. In conclusion, amiodarone displays broad-based fungicidal activity and may be acting in part by perturbing the calcium balance.
| |
Introduction |
|---|
|
|
|---|
AIDS
is defined by the occurrence of at least one of more than two dozen
opportunistic infections. Opportunistic fungal infections, such as
candidiasis, cryptococcosis, and histoplasmosis, occur frequently in
patients with AIDS. Among the opportunistic infections, fungal
infections caused by Pneumocystis, Candida,
Cryptococcus, or Histoplasma were the first to
occur in more than 50% of persons with AIDS; at time of death, nearly
85% of decedents had a fungal infection (Sugar, 1991
; Kwon-Chung and
Bennett, 1992
; Stansell, 1993
; Mitchell and Perfect, 1995
; Jones et
al., 1999
; Bastert et al., 2001
). Certain systemic fungal infections
have a high mortality rate among cancer patients as well (Viscoli et
al., 1997
).
There is intense interest in identifying new drugs with different modes
of action against fungal infections (DiDomenico, 1999
). The current
repertoire of antifungals has limitations such as insufficient
efficacy, the need for intravenous administration, serious side
effects, or the appearance of resistant fungal strains (Graybill,
1996
). Importantly, most of the current treatments are fungistatic and
subsequent clearing of these fungi is inadequate in patients with
defective immune systems. Thus, it is imperative to identify cellular
targets that, when impaired, lead to fungal cell death.
We have identified a new antifungal activity displayed by amiodarone, a
drug now in clinical use as an antiarrhythmic (Mason, 1987
; Gill et
al., 1992
; Roden, 1996
; Singh, 1996
). Amiodarone had been reported to
bind directly to mammalian heterotrimeric G proteins, thereby
activating them (Hagelüken et al., 1995
). While testing for
amiodarone's ability to affect G protein-mediated processes in fungi
under study in our laboratory, it was found that amiodarone
dramatically affected the growth of the fungal cells. The
growth-inhibitory effect was examined further, and amiodarone was found
to have potent fungicidal activity against a broad range of fungi,
including those of clinical importance.
| |
Materials and Methods |
|---|
|
|
|---|
Strains, Media, and Reagents.
The Cryptococcus
neoformans strains used were JEC21 (MAT
) and 271 (MAT
; provided by Dr. T. Kozel, University of Nevada, Reno, NV). The Aspergillus fumigatus was American Type
Culture Collection strain B-5233 (provided by Dr. R. Washburn,
University of Nevada, Reno, NV). The Saccharomyces
cerevisiae strains were BC159 (MATa ade2
ura3-52 leu2-3,112 his3) and FY70 (MATa ade1
trp1 leu2 his3 ura3; provided by Dr. S. Garret, University of
Medicine and Dentistry of New Jersey, Newark, NJ).
Growth Rates and Viability.
For quantitation of cell
proliferation, cells were grown in 5 ml of liquid medium in Klett test
tubes with vigorous shaking in a water bath. Measurement of cell
density was done in a Klett-Summerson colorimeter. Cells were grown
overnight in the medium to be tested. Dilutions of the overnight
cultures were made into a series of test tubes containing fresh medium
and various concentrations of drug or DMSO. The cell densities were
monitored at time 0 (typically about 1-2 × 106 cells/ml) and over time (typically 8-10
points for each growth curve) up to about 10 h. The increase in
cell density was plotted versus time, and the resulting curves were
used to determine the generation time for each culture (Stanier et al.,
1976
). Each experiment was repeated three to eight times, and the mean
values for generation times are given in the text and tables along with their standard errors. This method for cell growth was used because it
is more accurate than standard macro- or microbroth methods (e.g., the
reliability values are typically greater than 0.99) and is highly reproducible.
Ca2+ Efflux. S. cerevisiae (FY70) cells were grown to mid exponential phase overnight in SD medium to a density of about 1 to 2 × 107 cells/ml. Two milliliters of cell culture was mixed with 1 µl of 45CaCl2 (19 µCi; ICN) and then incubated at 30°C for approximately 1 h to allow accumulation of the radionuclide by the cells. One milliliter of the radiolabeled cells was then filtered through an HAWP 0.45 µm membrane filter (Millipore Corporation, Bedford, MA) to collect cells. The cells were washed with 15 ml of H2O and resuspended in 2 ml of 1 mM sodium acetate, pH 5.0, 3 µM GdCl3. A 200-µl aliquot was collected for the zero time point by filtration with membranes presoaked in 5 mM nonradioactive CaCl2 and washed with 15 ml of 5 mM nonradioactive CaCl2 to remove any external 45Ca. Amiodarone (in DMSO) was added to the remaining cells at concentrations from 5 to 20 µM, and 200-µl samples were collected over time by filtration and washed as was the zero time aliquot. Any radiolabeled calcium released during the amiodarone treatment would be removed by the washing. The filtered cells were air dried and counted in 1 ml of scintillation fluid (Universol; ICN) in a Beckman Coulter (Fullerton, CA) LS 1701 liquid scintillation counter to determine the remaining cell-associated counts. An additional 1 ml of the same labeled cells was handled identically except cells were treated with DMSO as a control.
| |
Results |
|---|
|
|
|---|
Inhibition of Cryptococcal Growth by Amiodarone.
The effect of
amiodarone on the growth of C. neoformans cells was measured
in liquid cultures. JEC21 cells were grown overnight in SD minimal
medium (30°C) to mid/late exponential phase. At zero time, aliquots
were transferred into fresh SD medium containing either amiodarone or
DMSO as a control. Cell densities (which began at about 1-2 × 106 cells/ml) were measured over an approximately
10-h period, and the results were plotted to produce growth curves.
Figure 1 shows dose-response curves for
cells treated with varying concentrations (1-10 µM) of amiodarone.
Each curve is the mean of four independent experiments, and rates of
increase were used to determine the generation times (Table
1). During this period, the control cells (which received only DMSO) increased in density about 10-fold to around
1.5 × 107 cells/ml and grew at a rate of
136 min/generation (Table 1). Addition of 1 µM amiodarone did not
alter the generation time of the JEC21 cells, whereas addition of 3 µM amiodarone doubled the length of the generation time (to 273 min/generation). Thus, the MIC50 for
amiodarone against JEC21 at 30°C is 2 µg/ml. Addition of amiodarone
at 5 µM or above prevented virtually any increase in cell density
during this period. Growth of Cryptococcus at high
temperature is an important virulence factor for this fungus; thus, we
examined the effect of amiodarone on the growth of cells at 37°C.
Whereas no effect on growth was seen in cultures with 1 µM
amiodarone, cultures containing 3 µM amiodarone displayed growth
rates of 432 min/generation, which is about 58% slower than that at
30°C, showing an exacerbating effect of higher temperature. As with
30°C, no increase in cell density occurred in cultures treated with 5 µM amiodarone or greater. Thus, amiodarone treatment dramatically
inhibits cryptococcal proliferation.
|
|
Amiodarone is Effective Against a Broad Range of Fungi. The antifungal activity of amiodarone is effective against a range of different fungi. Amiodarone was tested on S. cerevisiae and A. fumigatus (Table 1). Amiodarone inhibited the growth of S. cerevisiae strain BC159 but required a slightly higher concentration, in the 15 µM range, to completely stop proliferation. Amiodarone was also effective in preventing the growth of Aspergillus nidulans, although nearly 50 µM amiodarone was required to completely inhibit growth. The MIC50 against this strain of Aspergillus is about 4 µg/ml. Similar growth-inhibitory activity by amiodarone was seen against Fusarium oxysporum and Candida albicans (data not shown). Thus, amiodarone blocked the proliferation of Heterobasidiomycetes (Cryptococcus), Ascomycetes (Saccharomyces), and Hyphomycetes (Aspergillus).
Fungicidal Effect.
The lack of measurable growth in
cryptococcal cultures treated with 10 µM amiodarone could have been
due to a fungicidal or fungistatic effect. To differentiate between
these possibilities, JEC21 cells were grown in SD minimal medium and
treated with either 10 µM amiodarone or the DMSO control. Aliquots of
the treated cultures were taken at the time that drug was added (zero
hour) and at various times up to 50 h later (see Materials
and Methods) and spread on SD minimal plates to allow viable cells
to form colonies. The viability of cells treated with amiodarone
decreased rapidly (Table 2), with a
10-fold decrease in viable cells after only 1 h of exposure and a
200-fold decrease after 10 h. After about 1 day of treatment, only
0.001% of the cells were viable, whereas after about 2 days, no viable
cells remained.
|
Effect of Cations on Sensitivity to Amiodarone.
It has been
suggested that amiodarone affects calcium, sodium, and potassium ion
channels in mammalian cells. We tested whether addition of cations to
the growth medium would affect the growth inhibition caused by
amiodarone. Cryptococcal cells (JEC21) growing in SD minimal medium
were treated with 4 µM amiodarone to cause a marked decrease (but not
total inhibition) in their growth rate. In parallel cultures, cells
were simultaneously given either 10 mM CaCl2, 10 mM MgCl2, 10 mM KCl, or 20 mM NaCl . Control
cultures received the salt additions without amiodarone. The growth
rates of each culture were followed over several hours and generation times were determined (Table 3). A 4-µM
amiodarone treatment caused a lengthening of the generation time to
422.3 min compared with 162.4 min for the DMSO control. The addition of
CaCl2 was very effective in antagonizing the
amiodarone-induced inhibition, allowing a generation time (190.5 min)
close to that of the control, whereas treatment with
MgCl2 weakly suppressed growth inhibition (generation time of 216.7 min.). Addition of NaCl had a minor effect on
the generation time (281.5 min.) compared with the amiodarone-only treatment, whereas addition of KCl did not alter the generation time.
The addition of the salts by themselves (except KCl) resulted in slight
lengthening of the generation times (Table 3). Thus, addition of
divalent cations, in particular, calcium, to the growth medium
antagonized the growth-inhibitory effects caused by amiodarone, suggesting that amiodarone affects cation metabolism in particular.
|
Efflux of Radiolabeled Calcium Promoted by Amiodarone.
The
ability of high concentrations of calcium to protect cells from growth
inhibition by amiodarone suggested effects on calcium homeostatis.
Efflux of radiolabeled calcium was measured in the S. cerevisiae strain FY70. Cells were incubated in growth medium containing 9.5 µCi/ml 45Ca (as
45CaCl2) for 1 h to
allow accumulation of labeled calcium. Cells were subsequently sampled,
washed free of external labeled calcium, and suspended in sodium
acetate buffer. A zero time sample was taken, and then cells were
treated with amiodarone or DMSO and aliquots were taken over time. All
samples were filtered and washed with 5 mM nonradioactive
CaCl2 to remove any labeled calcium that may have
effluxed from the cells. The remaining cell-associated radioactivity
was determined by measuring cell filtrates in a scintillation counter.
Approximately 65% of the radiolabeled calcium remained associated with
control cells treated with DMSO over the 5-min course of the experiment
(Fig. 2A). In contrast, cells exposed to
10 µM amiodarone retained only about 35% of the labeled calcium. The
efflux of calcium upon amiodarone addition was very rapid, with the
majority of the loss occurring in less than 30 s. The efflux of
the labeled calcium upon amiodarone treatment was dose-dependent. Cells
treated with 2.5 µM amiodarone lost virtually the same percentage of
labeled calcium as did the control cells (25% at 20 s), whereas
cells treated with 5 and 10 µM amiodarone lost increasing amounts of
calcium (50% and 60% loss at 20 s, respectively). Increasing the
concentration of amiodarone to 20 µM did not further increase calcium
loss.
|
| |
Discussion |
|---|
|
|
|---|
We have shown here that amiodarone has antifungal activity against
a range of different fungi, including those of clinical importance,
such as C. neoformans. The growth-inhibitory effect was
shown to be fungicidal against Cryptococcus, resulting in about 90% killing within approximately 1 h of treatment.
Treatment with amiodarone caused immediate loss of calcium from cells,
and this may be the cause for subsequent cell death. Consistent with a
role that calcium loss may play, incubating cells in the presence of
very high concentrations (10 mM) of calcium effectively suppressed the
growth-inhibitory effects of amiodarone, whereas 10 mM
MgCl2 had only a slightly protective effect. The
presence of very high NaCl (20 mM) or KCl (10 mM) had little or no
protective effect. Such suppressive effects of calcium and magnesium on
growth inhibition by amiodarone are similar to the suppressive effects
of these ions on killing mediated by the KP4 antifungal protein from
Ustilago maydis (Gu et al., 1995
). KP4 was shown to
specifically inhibit voltage-gated Ca2+ channels
in mammalian cells. These results point to a mechanism for amiodarone
antifungal activity by the theory that amiodarone constitutively opens
a calcium channel, thereby allowing efflux of a significant amount of
cytoplasmic calcium. This calcium loss may be involved in growth
inhibition and subsequent cell death, although alternative mechanisms
for the effects of amiodarone are possible.
Calcium is known to be involved in controlling numerous cell processes
and is essential for cell growth (for review see Brown et al., 1995
;
Clapham, 1995
; Berridge et al., 1998
). The role of calcium in
microorganisms is still not well understood (O'Day, 1990
). Mutations
in numerous calcium-binding proteins, such as calmodulin, can affect
cell proliferation (Ohya and Anraku, 1992
). Some of these mutations can
be suppressed by the addition of very high concentrations of calcium to
the growth medium. There are several yeast proteins that are predicted
to be calcium transporters, including some in the plasma membrane
related to mammalian calcium channels (Nelissen et al., 1997
). The
availability of yeast strains with deletions of most of the genes
encoding these proteins will allow a determination of a role, if any,
in amiodarone sensitivity. Ion channels are now being recognized as
components of growth-regulatory signaling networks. For example, Rane
(1999)
demonstrated that there is a calcium-activated potassium channel
that is up-regulated by growth factors in fibroblasts. When this
channel was blocked, cell proliferation was inhibited. Ion channels as
targets for growth control of fungi is revealed by the finding that the
U. maydis fungal toxin is capable of inhibiting a calcium
channel (Gu et al., 1995
).
Fungi, including C. neoformans, are among the most common
primary opportunistic infections to occur in HIV-infected
patients (Sugar, 1991
; Kwon-Chung and Bennett, 1992
; Stansell, 1993
;
Mitchell and Perfect, 1995
). Familiar fungal pathogens have become
increasingly common clinical problems, with new fungal pathogens also
now being recognized (Perfect and Schell, 1996
). Treatments for
pathogenic fungi have been moderately successful but have been
associated with side effects and resistant strains (Graybill, 1996
).
There has also been a rise in infections by fungi, such as
Aspergillus, that are innately resistant to common
therapeutics, such as fluconazole. Furthermore, the commonly used
therapeutics are fungistatic and rely on the host's immune system for
clearing the growth-arrested cells, which is a problem in
immunocompromised patients. Thus, there is an ongoing need to identify
new fungal targets and therapeutics (DiDomenico, 1999
), in particular
those that have fungicidal activity. Although it is tempting to
conclude from our data that amiodarone may be just such an antifungal,
there are significant adverse side effects of long-term amiodarone use
that preclude its systemic use.
Amiodarone was developed over 30 years ago as an antianginal but is now
widely used as a potent antiarrhythmic drug (Mason, 1987
; Gill et al.,
1992
; Roden, 1996
; Singh, 1996
). It has been successfully used in the
treatment of symptomatic and life-threatening ventricular arrhythmias
and severe supraventricular arrhythmias. The plasma concentrations of
amiodarone that are used clinically for treatment of arrhythmia can be
in the range of 1 to 4 µM during loading periods. However, in
research studies, plasma concentrations in the 10 µM range have been
achieved. These are concentrations that are marginally effective
against Cryptococcus in vitro. It was originally described
as a class III antiarrhythmic because of its ability to increase the
action potential duration. However, class I antiarrhythmic effects and
a propensity to noncompetitively antagonize
- and
-adrenergic
receptors have also been seen. Although its precise mode of action
remains uncertain, amiodarone has been shown to block potassium
channels and inactive sodium channels (more so than activated ones), as
well as calcium channels (Kodama et al., 1999
; Nattel and Singh, 1999
;
Dorian, 2000
). Amiodarone has also been shown to directly activate G
proteins (Hagelüken et al., 1995
). The results presented here are
intriguing in that growth inhibition of amiodarone depends only on its
effects on calcium homeostasis but not that of sodium or potassium. A
significant difference between the effect of amiodarone in yeast versus
mammalian cells is that it induces an immediate calcium efflux in
yeast, whereas it blocks channel activity in mammalian cells. The
ability of amiodarone to induce calcium efflux suggests that amiodarone may be a useful new tool to study calcium homeostasis in yeast. Moreover, the ability to study amiodarone effects in yeast may provide
insights into its molecular activity in higher eukaryotes.
In summary, amiodarone has broad-spectrum antifungal activity and demonstrates a rapid fungicidal effect. Amiodarone promotes a rapid efflux of calcium, suggesting that calcium homeostasis is responsible, at least in part, for its inhibitory effects. The potent antifungal activity of amiodarone reveals a new mechanism for future antifungal development. Because amiodarone was developed as an antianginal, it is quite possible that derivatives may have increased antifungal activity and reduced toxicity. In addition, research into the molecular mechanism responsible for its antifungal activity may suggest alternative agents that affect the same target.
| |
Acknowledgments |
|---|
I thank John Sutko for enlightening discussions.
| |
Footnotes |
|---|
Accepted for publication October 8, 2001.
Received for publication September 10, 2001.
This study was supported by National Science Foundation Grant MCB-9513713 (to W.E.C.).
Address correspondence to: Dr. William E. Courchesne, Department of Microbiology, Mail Stop 320, University of Nevada, Reno, NV 89557. E-mail: wec{at}med.unr.edu
| |
Abbreviations |
|---|
AIDS, acquired immunodeficiency syndrome; SD, 0.17% (w/v) Difco yeast nitrogen base without amino acids and ammonium sulfate, 0.4% (w/v) ammonium sulfate, 2% (w/v) glucose; DMSO, dimethyl sulfoxide; HIV, human immunodeficiency virus.
| |
References |
|---|
|
|
|---|
a life and death signal.
Nature (Lond)
395:
645-648[CrossRef][Medline].This article has been cited by other articles:
![]() |
X. Serrano-Martin, Y. Garcia-Marchan, A. Fernandez, N. Rodriguez, H. Rojas, G. Visbal, and G. Benaim Amiodarone Destabilizes Intracellular Ca2+ Homeostasis and Biosynthesis of Sterols in Leishmania mexicana Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1403 - 1410. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Maresova, S. Muend, Y.-Q. Zhang, H. Sychrova, and R. Rao Membrane Hyperpolarization Drives Cation Influx and Fungicidal Activity of Amiodarone J. Biol. Chem., January 30, 2009; 284(5): 2795 - 2802. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Guo, S. Sun, J. Yu, Y. Li, and L. Cao Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods J. Med. Microbiol., April 1, 2008; 57(4): 457 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Q. Zhang and R. Rao Global Disruption of Cell Cycle Progression and Nutrient Response by the Antifungal Agent Amiodarone J. Biol. Chem., December 28, 2007; 282(52): 37844 - 37853. [Abstract] [Full Text] [PDF] |
||||
![]() |
N.-N. Zhang, D. D. Dudgeon, S. Paliwal, A. Levchenko, E. Grote, and K. W. Cunningham Multiple Signaling Pathways Regulate Yeast Cell Death during the Response to Mating Pheromones Mol. Biol. Cell, August 1, 2006; 17(8): 3409 - 3422. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Pozniakovsky, D. A. Knorre, O. V. Markova, A. A. Hyman, V. P. Skulachev, and F. F. Severin Role of mitochondria in the pheromone- and amiodarone-induced programmed death of yeast J. Cell Biol., January 17, 2005; 168(2): 257 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Afeltra, R. G. Vitale, J. W. Mouton, and P. E. Verweij Potent Synergistic In Vitro Interaction between Nonantimicrobial Membrane-Active Compounds and Itraconazole against Clinical Isolates of Aspergillus fumigatus Resistant to Itraconazole Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1335 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Gupta, V.-K. Ton, V. Beaudry, S. Rulli, K. Cunningham, and R. Rao Antifungal Activity of Amiodarone Is Mediated by Disruption of Calcium Homeostasis J. Biol. Chem., August 1, 2003; 278(31): 28831 - 28839. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||